Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2026, specifically reporting on share repurchase transactions executed between June 8 and June 12, 2026. The company is a global biopharma firm headquartered in London, United Kingdom.
Key Financial Metrics and Transaction Details
The filing details a non-discretionary share buyback program executed through Citigroup Global Markets Limited. The following table summarizes the daily purchase activity:
| Date | Shares Purchased | Lowest Price (GBp) | Highest Price (GBp) | VWAP (GBp) |
|---|---|---|---|---|
| 8 June 2026 | 225,237 | 1,904.50 | 1,937.50 | 1,916.92 |
| 9 June 2026 | 228,524 | 1,840.50 | 1,912.00 | 1,882.23 |
| 10 June 2026 | 222,449 | 1,892.50 | 1,929.00 | 1,913.02 |
| 11 June 2026 | 220,242 | 1,912.50 | 1,972.50 | 1,953.34 |
| 12 June 2026 | 215,972 | 1,962.50 | 2,008.00 | 1,983.00 |
Cumulative Activity: Since the program's announcement on May 11, 2026, the company has purchased a total of 7,346,236 ordinary shares.
Capital Structure: Following these purchases, GSK holds 268,724,522 ordinary shares in treasury. The total number of ordinary shares in issue (excluding treasury shares) is 4,047,527,077. Treasury shares represent 6.64% of the total voting rights.
Material Changes
The filing reports a reduction in the number of shares in issue due to the buyback program. The filing text does not provide comparative financial data (revenue, profit, cash flow) or material changes to operational metrics versus prior periods, as this report is limited to share transaction disclosures.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future earnings or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the 2025 Annual Report on Form 20-F and the Q1 2026 Results. The share purchases were executed pursuant to a non-discretionary agreement entered into on May 8, 2026.
Investor Verification Checklist
- Verify the total number of treasury shares held (268,724,522) against the company's latest capitalization table.
- Confirm the remaining authorization under the existing buyback program to assess future repurchase capacity.
- Review the 2025 Form 20-F and Q1 2026 Results for the specific risk factors referenced in the cautionary statement.
- Check the London Stock Exchange RNS link provided in the filing for the full breakdown of individual trades on CHIX and BATE order books.